iScience (Oct 2022)
Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection
- A.H. Ayesha Lavell,
- Jonne J. Sikkens,
- Arthur W.D. Edridge,
- Karlijn van der Straten,
- Ferdyansyah Sechan,
- Melissa Oomen,
- David T.P. Buis,
- Michiel Schinkel,
- Judith A. Burger,
- Meliawati Poniman,
- Jacqueline van Rijswijk,
- Menno D. de Jong,
- Godelieve J. de Bree,
- Edgar J.G. Peters,
- Yvo M. Smulders,
- Rogier W. Sanders,
- Marit J. van Gils,
- Lia van der Hoek,
- Marije K. Bomers
Affiliations
- A.H. Ayesha Lavell
- Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Internal Medicine, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- Jonne J. Sikkens
- Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Internal Medicine, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Corresponding author
- Arthur W.D. Edridge
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Karlijn van der Straten
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Internal Medicine, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Ferdyansyah Sechan
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Melissa Oomen
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- David T.P. Buis
- Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Internal Medicine, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- Michiel Schinkel
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC Location Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Judith A. Burger
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Meliawati Poniman
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Jacqueline van Rijswijk
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Menno D. de Jong
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Godelieve J. de Bree
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Internal Medicine, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Edgar J.G. Peters
- Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Internal Medicine, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- Yvo M. Smulders
- Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Internal Medicine, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- Rogier W. Sanders
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
- Marit J. van Gils
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Lia van der Hoek
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- Marije K. Bomers
- Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Internal Medicine, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Corresponding author
- Journal volume & issue
-
Vol. 25,
no. 10
p. 105105
Abstract
Summary: Antibodies against seasonal human coronaviruses (HCoVs) are known to cross-react with SARS-CoV-2, but data on cross-protective effects of prior HCoV infections are conflicting. In a prospective cohort of healthcare workers (HCWs), we studied the association between seasonal HCoV (OC43, HKU1, 229E and NL63) nucleocapsid protein IgG and SARS-CoV-2 infection during the first pandemic wave in the Netherlands (March 2020 – June 2020), by 4-weekly serum sampling. HCW with HCoV-OC43 antibody levels in the highest quartile, were less likely to become SARS-CoV-2 seropositive when compared with those with lower levels (6/32, 18.8%, versus 42/97, 43.3%, respectively: p = 0.019; HR 0.37, 95% CI 0.16–0.88). We found no significant association with HCoV-OC43 spike protein IgG, or with antibodies against other HCoVs. Our results indicate that the high levels of HCoV-OC43-nucleocapsid antibodies, as an indicator of a recent infection, are associated with protection against SARS-CoV-2 infection; this supports and informs efforts to develop pancoronavirus vaccines.
